1. Home
  2. Analysis
  3. Rad001

Rad001: effectiveness, side effects, alternatives

Summary:

Rad001: everolimus

We study 185 Rad001 users. The information eHealthMe analyzes includes:

- Effectiveness of Rad001
- Alternative drugs to Rad001
- 513 Rad001 side effects and drug interactions

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

Number of reports submitted per year:

Rad001: 185 reports from FDA and social media.

Common Rad001 side effects:

Rad001 side effects by duration, gender and age:

Browse all side effects of Rad001:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Rad001 and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Do you take Rad001?

- You can start a phase IV clinical trial to monitor Rad001 safety and effectiveness.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

How we gather our data?

Healthcare data is obtained from a number of sources including the Food and Drug Administration (FDA). This information is aggregated and used to produce personalized reports that patients can reference. Browse all drugs on eHealthMe.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.